Pathogenicity of Pandemic H1N1 Influenza A Virus in Immunocompromised Cynomolgus Macaques

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Pham, Van Loi ^a   Nakayama, Misako ^a   Itoh, Yasushi ^a   Ishigaki, Hirohito ^a   Kitano, Mitsutaka ^a   Arikata, Masahiko ^a   Ishida, Hideaki ^a   Kitagawa, Naoko ^a   Shichinohe, Shintaro ^b   Okamatsu, Masatoshi ^b   Sakoda, Yoshihiro ^b   Tsuchiya, Hideaki ^a   Nakamura, Shinichiro ^a   Kida, Hiroshi ^b,c   Ogasawara, Kazumasa ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOKINESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; HISTOLOGY; IMMUNE DEFICIENCY; INFLUENZA VIRUS A H1N1; LUNG INFECTION; LUNG PARENCHYMA; MACACA FASCICULARIS; MORBIDITY; NONHUMAN; NOSE SMEAR; PROTEIN LOCALIZATION; VIRUS IDENTIFICATION; VIRUS VIRULENCE;

ANIMALS; CYCLOPHOSPHAMIDE; CYCLOSPORINE; CYTOKINES; IMMUNOCOMPROMISED HOST; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSION; INFLUENZA A VIRUS, H1N1 SUBTYPE; LUNG; MACACA FASCICULARIS; ORTHOMYXOVIRIDAE INFECTIONS; VIRUS REPLICATION;

EID: 84884521624     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075910     Document Type: Article

References (62)

1. Writing committee of the WHO consultation on clinical aspects of pandemic (H1N1) 2009 influenza (2009) Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 362(1708-1719).
2. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-1025. PubMed: 19672242.
3. Munster VJ, de Wit E, van den Brand JM, Herfst S, Schrauwen EJ, et al. (2009) Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 325: 481-483. PubMed: 19574348.
4. Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, et al. (2009) Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 325: 484-487. PubMed: 19574347.
5. Herfst S, van den Brand JM, Schrauwen EJ, de Wit E, Munster VJ, et al. (2010) Pandemic 2009 H1N1 influenza virus causes diffuse alveolar damage in cynomolgus macaques. Vet Pathol 47: 1040-1047. doi:10.1177/0300985810374836. PubMed: 20647595.
6. Almansa R, Bermejo-Martín JF, de Lejarazu Leonardo RO, (2012) Immunopathogenesis of 2009 pandemic influenza. Enferm Infecc Microbiol Clin 30 (Suppl 4):: 18-24. doi:10.1016/j.eimc.2011.07.013. PubMed: 23116788.
7. Viasus D, Antón A, Pumarola T, Carratalà J, (2012) Influenza A(H1N1)pdm09: beyond the pandemic. Enferm Infecc Microbiol Clin 30 (Suppl 4):: 54-57. doi:10.1016/S0213-005X(12)70106-4. PubMed: 23116794.
8. Morlighem JE, Aoki S, Kishima M, Hanami M, Ogawa C, et al. (2011) Mutation analysis of 2009 pandemic influenza A(H1N1) viruses collected in Japan during the peak phase of the pandemic. PLOS ONE 6: e18956. doi:10.1371/journal.pone.0018956. PubMed: 21572517.
9. Kao CL, Chan TC, Tsai CH, Chu KY, Chuang SF, et al. (2012) Emerged HA and NA mutants of the pandemic influenza H1N1 viruses with increasing epidemiological significance in Taipei and Kaohsiung, Taiwan, 2009-10. PLOS ONE 7: e31162. doi:10.1371/journal.pone.0031162. PubMed: 22328930.
10. de la Rosa-Zamboni D, Vázquez-Pérez JA, Avila-Ríos S, Carranco-Arenas AP, Ormsby CE, et al. (2012) Molecular characterization of the predominant influenza A(H1N1)pdm09 virus in Mexico, December 2011-February 2012. PLOS ONE 7: e50116. doi:10.1371/journal.pone.0050116. PubMed: 23209653.
11. Makkoch J, Suwannakarn K, Payungporn S, Prachayangprecha S, Cheiocharnsin T, et al. (2012) Whole genome characterization, phylogenetic and genome signature analysis of human pandemic H1N1 virus in Thailand, 2009-2012. PLOS ONE 7: e51275. doi:10.1371/journal.pone.0051275. PubMed: 23251479.
12. Green LC, Didier PJ, Bowers LC, Didier ES, (2004) Natural and experimental infection of immunocompromised rhesus macaques (Macaca mulatta) with the microsporidian Enterocytozoon bieneusi genotype D. Microbes Infect 6: 996-1002. doi:10.1016/j.micinf.2004.05.012. PubMed: 15345231.
13. Wumba R, Longo-Mbenza B, Menotti J, Mandina M, Kintoki F, et al. (2012) Epidemiology, clinical, immune, and molecular profiles of microsporidiosis and Cryptosporidiosis among HIV/AIDS patients. Int J Gen Med 5: 603-611. PubMed: 22924007.
14. Kolappaswamy K, Shipley ST, Tatarov II, DeTolla LJ, (2008) Methicillin-resistant Staphylococcus non-aureus infection in an irradiated rhesus macaque (Macaca mulatta). J Am Assoc Lab Anim Sci 47: 64-67. PubMed: 18459716.
15. Siberry GK, Frederick T, Emmanuel P, Paul ME, Bohannon B, et al. (2012) Methicillin-resistant Staphylococcus aureus infections in human immunodeficiency virus-infected children and adolescents. AIDS Res Treat,(2012): pp. 627974. PubMed: 23008761.
16. Schröder C, Pfeiffer S, Wu G, Azimzadeh AM, Aber A, et al. (2006) Simian parvovirus infection in cynomolgus monkey heart transplant recipients causes death related to severe anemia. Transplantation 81: 1165-1170. doi:10.1097/01.tp.0000203170.77195.e4. PubMed: 16641603.
17. Rerolle JP, Morelon E, Helal I, Peraldi MN, Mamzer-Bruneel MF, et al. (2004) Parvovirus B19-related anaemia after renal transplantation. Scand J Infect Dis 36: 513-516. doi:10.1080/00365540410020244. PubMed: 15307588.
18. Chernak E, Dubin G, Henry D, Naides SJ, Hodinka RL, et al. (1995) Infection due to parvovirus B19 in patients infected with human immunodeficiency virus. Clin Infect Dis 20: 170-173. doi:10.1093/clinids/20.1.170. PubMed: 7727646.
19. Lednicky JA, Arrington AS, Stewart AR, Dai XM, Wong C, et al. (1998) Natural isolates of simian virus 40 from immunocompromised monkeys display extensive genetic heterogeneity: new implications for polyomavirus disease. J Virol 72: 3980-3990. PubMed: 9557685.
20. Tan CS, Dezube BJ, Bhargava P, Autissier P, Wüthrich C, et al. (2009) Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis 199: 881-888. doi:10.1086/597117. PubMed: 19434914.
21. Ohtaki S, Kodama H, Hondo R, Kurata T, (1986) Activation of cytomegalovirus infection in immunosuppressed cynomolgus monkeys inoculated with varicella-zoster virus. Acta Pathol Jpn 36: 1537-1552. PubMed: 3026140.
22. Hurd J, Heath RB, (1975) Effect of cyclophosphamide on infections in mice caused by virulent and avirulent strains of influenza virus. Infect Immun 11: 886-889. PubMed: 1168172.
23. Schuurman HJ, Smith HT, Cozzi E, (2005) Tolerability of cyclosphosphamide and methotrexate induction immunosuppression in nonhuman primates. Toxicology 213: 1-12. doi:10.1016/j.tox.2005.03.017. PubMed: 15970369.
24. Sogawa H, Boskovic S, Nadazdin O, Abrahamian G, Colvin RB, et al. (2008) Limited efficacy and unacceptable toxicity of cyclophosphamide for the induction of mixed chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 86: 615-619. doi:10.1097/01.tp.0000330808.36393.93. PubMed: 18724233.
25. Buss J, Essig E, Osei K, Brodsky S, Hadley G, et al. (2011) Steroid-free maintenance of islet allografts using mycophenolate mofetil and cyclosporine in the non-human primate. Ann Transplant 16: 88-97. PubMed: 21716191.
26. Solbach W, Lange CE, Rollinghoff M, Wagner H, (1984) Growth, interleukin-2 production, and responsiveness to IL-2 in T4-positive T Lymphocyte populations from malignant cutaneous T cell lymphoma (Sezary's syndrome): the effect of cyclosporin A. Blood 64: 1022-1027. PubMed: 6237693.
27. Masri MA, (2003) The mosaic of immunosuppressive drugs. Mol Immunol 39: 1073-1077. doi:10.1016/S0161-5890(03)00075-0. PubMed: 12835079.
28. Chan MC, Chan RW, Yu WC, Ho CC, Chui WH, et al. (2009) Influenza H5N1 virus infection of polarized human alveolar epithelial cells and lung microvascular endothelial cells. Respir Res 10: 102. doi:10.1186/1465-9921-10-102. PubMed: 19874627.
29. Nelli RK, Dunham SP, Kuchipudi SV, White GA, Baquero-Perez B, et al. (2012) Mammalian innate resistance to highly pathogenic avian influenza H5N1 virus infection is mediated through reduced proinflammation and infectious virus release. J Virol 86: 9201-9210. doi:10.1128/JVI.00244-12. PubMed: 22718824.
30. Sakabe S, Iwatsuki-Horimoto K, Takano R, Nidom CA, Le M, et al. (2011) Cytokine production by primary human macrophages infected with highly pathogenic H5N1 or pandemic H1N1 2009 influenza viruses. J Gen Virol 92: 1428-1434. doi:10.1099/vir.0.030346-0. PubMed: 21367984.
31. Nakajima N, Van Tin N, Sato Y, Thach HN, Katano H, et al. (2012) Pathological study of archival lung tissues from five fatal cases of avian H5N1 influenza in Vietnam. Mod Pathol 26: 357-369. PubMed: 23174938.
32. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, et al. (1998) Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest 101: 643-649. doi:10.1172/JCI1355. PubMed: 9449698.
33. Kozak W, Kluger MJ, Soszynski D, Conn CA, Rudolph K, et al. (1998) IL-6 and IL-1β in fever. Studies using cytokine-deficient (knockout) mice. Ann N Y Acad Sci 856: 33-47. doi:10.1111/j.1749-6632.1998.tb08310.x. PubMed: 9917862.
34. Van Reeth K, (2000) Cytokines in the pathogenesis of influenza. Vet Microbiol 74: 109-116. doi:10.1016/S0378-1135(00)00171-1.
35. Nakae H, Endo S, Inoue Y, Fujino Y, Wakabayashi G, et al. (2003) Matrix metalloproteinase-1 and cytokines in patients with acute pancreatitis. Pancreas 26: 134-138. doi:10.1097/00006676-200303000-00008.
36. Carlson CM, Turpin EA, Moser LA, O'Brien KB, Cline TD, et al. (2010) Transforming growth factor-β: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis. PLOS Pathog 6: e1001136.
37. Liu X, Zhao Z, Li Z, Xu C, Sun L, et al. (2012) Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and-independent pathways. PLOS ONE 7: e37277. doi:10.1371/journal.pone.0037277.
38. Cook RM, (1983) Activity of cyclosporin A in experimental influenza virus infection in mice. Agents Actions 13: 98-100. doi:10.1007/BF01994290.
39. Schiltknecht E, Ada GL, (1985) In vivo effects of cyclosporine on influenza A virus-infected mice. Cell Immunol 91: 227-239. doi:10.1016/0008-8749(85)90046-2.
40. Singer SH, Noguchi P, Kirschstein RL, (1972) Respiratory diseases in cyclophosphamide-treated mice II. Decreased virulence of PR8 influenza virus. Infect Immun 5: 957-960.
41. Cooksley CD, Avritscher EB, Bekele BN, Rolston KV, Geraci JM, et al. (2005) Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer 104: 618-628. doi:10.1002/cncr.21203.
42. Cordero E, Aydillo T, Farinas MC, Pano-Pardo JR, Pachon J, et al. (2012) Immunosuppressed patients with pandemic influenza A 2009 (H1N1) virus infection. Eur J Clin Microbiol Infect Dis 31: 547-556. doi:10.1007/s10096-011-1346-3.
43. Kunisaki KM, Janoff EN, (2009) Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 9: 493-504. doi:10.1016/S1473-3099(09)70175-6.
44. Meerveld-Eggink A, de Weerdt O, van der Velden AM, Los M, van der Velden AW, et al. (2011) Response to influenza virus vaccination during chemotherapy in patients with breast cancer. Ann Oncol 22: 2031-2035. doi:10.1093/annonc/mdq728.
45. Huang KL, Armstrong JA, Ho M, (1983) Antibody response after influenza immunization in renal transplant patients receiving cyclosporin A or azathioprine. Infect Immun 40: 421-424.
46. Mazzone PJ, Mossad SB, Mawhorter SD, Mehta AC, Schilz RJ, et al. (2001) The humoral immune response to influenza vaccination in lung transplant patients. Eur Respir J 18: 971-976. doi:10.1183/09031936.01.00215201. PubMed: 11829104.
47. Soesman NM, Rimmelzwaan GF, Nieuwkoop NJ, Beyer WE, Tilanus HW, (2000) Efficacy of influenza vaccination in adult liver transplant recipients. J Med Virol 61: 85-93. doi:10.1002/(SICI)1096-9071(200005)61:1.
48. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG, (2006) Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 193: 760-764. doi:10.1086/500465. PubMed: 16479508.
49. van der Vries E, Stelma FF, Boucher CA, (2010) Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 363: 1381-1382. doi:10.1056/NEJMc1003749. PubMed: 20879894.
50. Koyama S, Ishii KJ, Kumar H, Tanimoto T, Coban C, et al. (2007) Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J Immunol 179: 4711-4720.
51. Nilsberth C, Elander L, Hamzic N, Norell M, Lonn J, et al. (2009) The role of interleukin-6 in lipopolysaccharide-induced fever by mechanisms independent of prostaglandin E2. Endocrinology 150: 1850-1860. doi:10.1210/en.2008-0806. PubMed: 19022895.
52. Brun-Buisson C, Richard JC, Mercat A, Thiébaut AC, Brochard L, (2011) Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 183: 1200-1206. doi:10.1164/rccm.201101-0135OC. PubMed: 21471082.
53. Xu T, Qiao J, Zhao L, He G, Li K, et al. (2009) Effect of dexamethasone on acute respiratory distress syndrome induced by the H5N1 virus in mice. Eur Respir J 33: 852-860. doi:10.1183/09031936.00130507.
54. Confalonieri M, Kodric M, Santagiuliana M, Longo C, Biolo M, et al. (2012) To use or not to use corticosteroids for pneumonia? A clinician's perspective. Monaldi Arch Chest Dis 77: 94-101.
55. Evseenko VA, Bukin EK, Zaykovskaya AV, Sharshov KA, Ternovoi VA, et al. (2007) Experimental infection of H5N1 HPAI in BALB/c mice. Virol J 4: 77. doi:10.1186/1743-422X-4-77. PubMed: 17662125.
56. Cilloniz C, Shinya K, Peng X, Korth MJ, Proll SC, et al. (2009) Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLOS Pathog 5: e1000604.
57. Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, Sabourin PJ, Long JP, et al. (2009) Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A 106: 3455-3460. doi:10.1073/pnas.0813234106. PubMed: 19218453.
58. Kawakami C, Obuchi M, Saikusa M, Noguchi Y, Ujike M, et al. (2009) Isolation of oseltamivir-resistant influenza A/H1N1 virus of different origins in Yokohama City, Japan, during the 2007-2008 influenza season. Jpn J Infect Dis 62: 83-86.
59. Shiino T, Okabe N, Yasui Y, Sunagawa T, Ujike M, et al. (2010) Molecular evolutionary analysis of the influenza A(H1N1)pdm, May-September, 2009: temporal and spatial spreading profile of the viruses in Japan. PLOS ONE 5: e11057. doi:10.1371/journal.pone.0011057.
60. Arikata M, Itoh Y, Okamatsu M, Maeda T, Shiina T, et al. (2012) Memory immune responses against pandemic (H1N1) 2009 influenza virus induced by a whole particle vaccine in cynomolgus monkeys carrying Mafa-A1*052:02. PLOS ONE 7: e37220. doi:10.1371/journal.pone.0037220.
61. Itoh Y, Ozaki H, Tsuchiya H, Okamoto K, Torii R, et al. (2008) A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques. Vaccine 26: 562-572. doi:10.1016/j.vaccine.2007.11.031. PubMed: 18164788.
62. Nicholls JM, Wong LP, Chan RW, Poon LL, So LK, et al. (2012) Detection of highly pathogenic influenza and pandemic influenza virus in formalin fixed tissues by immunohistochemical methods. J Virol Methods 179: 409-413. doi:10.1016/j.jviromet.2011.11.006.